 | |  | |  | |  | |  | |  | |  | |  |
| IJCEM Copyright © 2008-All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711 |
Int J Clin Exp Med 2012;5(3):238-244
Original Article
Multistrain probiotic preparation significantly reduces symptoms of irritable bowel
syndrome in a double-blind placebo-controlled study
Shusheng Cui, Ying Hu
Department of Medical Oncology, Huangpu District Center Hospital, Shanghai, China; Department of Gastroenterology, Xinhua
Hospital, University of Jiaotong, Shanghai,China
Received November 25, 2011; accepted April 28, 2012; Epub June 16, 2012; Published June 30, 2012
Abstract: Aim: To investigate the effect of bifid triple viable capsule, a multistrain probiotic preparation on symptoms of irritable bowel
syndrome (IBS), and the amount of fecal Bifidobacterium spp. and Lactobacillus spp. of IBS patients before and after treatment.
Methods: A total of 60 IBS patients who met Rome III criteria were included in this double-blind, randomized, and placebo-controlled
study. The patients were randomly assigned to receive composite probiotics or placebo for four weeks. The IBS symptoms of
participants were surveyed using a questionnaire, and the amount of fecal Bifidobacterium spp. and Lactobacillus spp. was
determined by quantitative Real-time PCR pre- and post-intervention. Results: During the four week intervention period, the patients
receiving probiotic preparation showed a significantly greater improvement in the symptom severity score of IBS, severity and frequency
of pain or discomfort, abdominal distention and satisfaction with bowel habits. The symptom subtypes revealed that low amounts of
both Bifidobacterium spp. and Lactobacillus spp. were present in the samples of diarrhea-predominant IBS patients, while the
alternating-predominant IBS patienets had only low amounts of Bifidobacterium spp. Post-intervention for diarrhea-predominant IBS
patients with lower symptom severity score showed even lower amounts of Bifidobacterium spp. and Lactobacillus spp. Conclusion:
Bifid triple viable capsule supplement may benefit patients with IBS. Multistrain probiotic preparation may be a promising candidate for
IBS therapy, althought the mechanism needs to be further studied. (IJCEM1111008)
Keywords: Irritable bowel syndrome, probiotics, real-time PCR, gut micribiota
Address all correspondence to:
Dr. Yin Hu
Department of Gastroenterology
Xinhua Hospital, University of Jiaotong
Shanghai 20002, China.
Tel: +86-021-18217799336; Fax: +86-021-65795173
E-mail: xyhuying@sohu.com
Original Article
Multistrain probiotic preparation significantly reduces symptoms of irritable bowel
syndrome in a double-blind placebo-controlled study
Shusheng Cui, Ying Hu
Department of Medical Oncology, Huangpu District Center Hospital, Shanghai, China; Department of Gastroenterology, Xinhua
Hospital, University of Jiaotong, Shanghai,China
Received November 25, 2011; accepted April 28, 2012; Epub June 16, 2012; Published June 30, 2012
Abstract: Aim: To investigate the effect of bifid triple viable capsule, a multistrain probiotic preparation on symptoms of irritable bowel
syndrome (IBS), and the amount of fecal Bifidobacterium spp. and Lactobacillus spp. of IBS patients before and after treatment.
Methods: A total of 60 IBS patients who met Rome III criteria were included in this double-blind, randomized, and placebo-controlled
study. The patients were randomly assigned to receive composite probiotics or placebo for four weeks. The IBS symptoms of
participants were surveyed using a questionnaire, and the amount of fecal Bifidobacterium spp. and Lactobacillus spp. was
determined by quantitative Real-time PCR pre- and post-intervention. Results: During the four week intervention period, the patients
receiving probiotic preparation showed a significantly greater improvement in the symptom severity score of IBS, severity and frequency
of pain or discomfort, abdominal distention and satisfaction with bowel habits. The symptom subtypes revealed that low amounts of
both Bifidobacterium spp. and Lactobacillus spp. were present in the samples of diarrhea-predominant IBS patients, while the
alternating-predominant IBS patienets had only low amounts of Bifidobacterium spp. Post-intervention for diarrhea-predominant IBS
patients with lower symptom severity score showed even lower amounts of Bifidobacterium spp. and Lactobacillus spp. Conclusion:
Bifid triple viable capsule supplement may benefit patients with IBS. Multistrain probiotic preparation may be a promising candidate for
IBS therapy, althought the mechanism needs to be further studied. (IJCEM1111008)
Keywords: Irritable bowel syndrome, probiotics, real-time PCR, gut micribiota
Address all correspondence to:
Dr. Yin Hu
Department of Gastroenterology
Xinhua Hospital, University of Jiaotong
Shanghai 20002, China.
Tel: +86-021-18217799336; Fax: +86-021-65795173
E-mail: xyhuying@sohu.com
